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Companion animals are susceptible to SARS-CoV-2 infection and sporadic cases of pet infections have occurred in
the United Kingdom. Here we present the first large-scale serological survey of SARS-CoV-2 neutralising anti-
bodies in dogs and cats in the UK. Results are reported for 688 sera (454 canine, 234 feline) collected by a large
veterinary diagnostic laboratory for routine haematology during three time periods; pre-COVID-19 (January
2020), during the first wave of UK human infections (April–May 2020) and during the second wave of UK human
infections (September 2020–February 2021). Both pre-COVID-19 sera and those from the first wave tested
negative. However, in sera collected during the second wave, 1.4% (n ¼ 4) of dogs and 2.2% (n ¼ 2) of cats tested
positive for neutralising antibodies. The low numbers of animals testing positive suggests pet animals are unlikely
to be a major reservoir for human infection in the UK. However, continued surveillance of in-contact susceptible
animals should be performed as part of ongoing population health surveillance initiatives.1. Introduction
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
emerged in Wuhan, China at the end of 2019 (Wu et al., 2020) and
rapidly spread around the world. The main route of transmission remains
human-to-human. However, there is evidence that the virus can infect
animals (Prince et al., 2021) and it is important that we remain vigilant of
such infections; particularly in companion animals with whom humans
often have close contact.
Although initially there were only sporadic cases of infection in cats
and dogs (Garigliany et al., 2020; Newman et al., 2020; Sit et al., 2020),
there are now numerous reports of infection detected by RT-PCR or virus
isolation (Barrs et al., 2020; Decaro et al., 2021; Hamer et al., 2021;
Ruiz-Arrondo et al., 2021; Sailleau et al., 2020), including in the UK
(Hosie et al., 2021). Evidence of infection of cats and dogs has also been
provided by the detection of anti-SARS-CoV-2 antibodies in several
studies worldwide (Fritz et al., 2021; Michelitsch et al., 2020, 2021;l Sciences, Brock University, St. C
rson).
.
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Experimental infections have shown that cats and, to a lesser extent, dogs
are susceptible to SARS-CoV-2 and that cats can transmit the virus to
other cats (Bosco-Lauth et al., 2020; Halfmann et al., 2020; Shi et al.,
2020). Infections in companion animals appear to have occurred as a
result of human-to-animal transmission; however, the reported trans-
mission of SARS-CoV-2 from farmed mink to in-contact humans, cats and
dogs (Oude Munnink et al., 2021; van Aart et al., 2021) and the detection
of the virus in stray dogs and cats (Dias et al., 2021; Villanueva-Saz et al.,
2021), suggest it is important to continue surveillance in companion
animals. Here we conducted a survey of SARS-CoV-2 neutralising anti-
bodies in cats and dogs attending UK veterinary practices.atharines, ON, L2S 3A1, Canada.
t 2021
rticle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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2.1. Samples
Canine and feline sera used in this study were obtained from the UK
Virtual Biobank, which uses health data from commercial diagnostic
laboratories participating in the Small Animal Veterinary Surveillance
Network (SAVSNET) to target left over diagnostic samples in the same
laboratories for enhanced phenotypic and genomic analyses (Smith et al.,
2021). All samples were residual sera remaining after routine diagnostic
testing and were sent by one contributing laboratory based on conve-
nience within the following parameters: samples were requested fromUK
cats and dogs collected over two time periods; March and April 2020
(during the first wave in humans) for both cats and dogs, then September
2020 to February 2021 for dogs, and January 2021 for cats (during the
second wave in humans). Serum samples collected from the same labo-
ratory in early January 2020 were also tested as pre-COVID-19 controls.
All samples were linked to electronic health data for that sample (species,
breed, sex, postcode of the submitting veterinary practice, date received
by the diagnostic laboratory) held in the SAVSNET database, using a
unique anonymised identifier. Data on SARS-CoV-2 exposure or symp-
toms was not available. Ethical approval to collect electronic health data
(SAVSNET) and physical samples from participating laboratoriesFig. 1. Schematic map showing the location of samples for which testing of SARS-
positive for SARS-CoV-2 neutralising antibodies using PRNT80. Blue dots indicate sa
figure legend, the reader is referred to the Web version of this article.)
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(National Virtual Biobank) was granted by the Research Ethics Com-
mittee at the University of Liverpool (RETH000964).
2.2. Neutralising antibody detection in serum samples
Serum samples were screened for SARS-CoV-2 neutralising antibodies
using the plaque reduction neutralisation test (PRNT) as previously
described (Patterson et al., 2020a), with the SARS-CoV
-2/human/Liverpool/REMRQ0001/2020 isolate cultured in Vero E6
cells (Patterson et al., 2020b). Briefly, sera were heat inactivated at 56 C
for 30 min and stored at20 C until use. DMEM containing 2% FBS was
used to dilute sera ten-fold followed by serial two-fold dilution.
SARS-CoV-2 at 800 plaque forming units (PFU)/ml was added to diluted
sera and incubated at 37 C for 1 h. The virus/serum mixture was then
inoculated onto Vero E6 cells, incubated at 37 C for 1 h, and overlaid as
in standard plaque assays (Rossi et al., 2015). Cells were incubated for
48 h at 37 C and 5% CO2, fixed with 10% formalin and stained with
0.05% crystal violet solution. PRNT80 was determined by the highest
dilution with 80% reduction in plaques compared to the control. Samples
with detectable neutralising antibody titre were repeated as technical
replicates for confirmation. Where titres differed between technical
replicates, the lowest dilution was reported.CoV-2 neutralising antibodies is reported. Red dots indicate samples that were
mples that were negative. (For interpretation of the references to colour in this
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A total of 732 samples were received from the diagnostic laboratory
and tested for SARS-CoV-2 neutralising antibodies. Linking of data to the
samples found that 22 samples were duplicates (duplicate samples gave
the same result in each replicate and are therefore reported as one
sample). Seven samples were from animals with non-UK postcodes, two
samples did not have species data, two samples were received as dogs but
were actually from cats and were collected outside the two time periods
of cat sample collection and eleven samples were missing postcodes;
these samples were excluded. Results are therefore reported for 688 sera
(454 canine, 234 feline) of which 558 (372 dogs, 186 cats) were collected
during the SARS-CoV-2 pandemic and 130 (82 dogs, 48 cats) were
collected from animals before the first confirmed human case in the UK
(21st January 2020 (Lillie et al., 2020)) - pre-COVID-19 samples; these
samples were distributed across the UK (Fig. 1). Of the dog sera collected
during the pandemic, 0/85 (0%) collected in March/April 2020 and
4/287 (1.4%) collected September 2020–February 2021 tested positive
for neutralising antibodies with titres of 1:20 (n ¼ 2) and 1:80 (n¼ 2). In
cats, 0/96 (0%) sera collected in March/April 2020 tested positive for
neutralising antibodies and 2/90 (2.2%) collected in January 2021 tested
positive with titres of 1:40 and 1:80. Pre-COVID-19 sera from both dogs
(n ¼ 82) and cats (n ¼ 48) tested negative for neutralising antibodies.
Positive samples in dogs were collected in November 2020 (n ¼ 1),
January 2021 (n ¼ 2) and February 2021 (n ¼ 1) and were collected in
Kent, Buckinghamshire, Worcestershire and Yorkshire, respectively
(Fig. 1). The two positive cats were collected in January 2021; one in
Birmingham and the other in London (Fig. 1).
4. Discussion
Studies of companion animals have shown that they can be infected
with SARS-CoV-2 (Prince et al., 2021). In the UK, there have been spo-
radic reports of infection in cats and dogs, including one that tested 387
cats showing respiratory signs using RT-PCR and found one cat to be
positive for the virus (Hosie et al., 2021; Ferasin et al., 2021). However,
there has been no large scale sero-survey of infection. Here we show that
a small proportion of UK dogs and cats, sampled at a time of active human
transmission, tested positive for SARS-CoV-2 neutralising antibodies.
Sera from two time points during the pandemic were analysed. Sera
collected during March and April 2020 (first wave) from both cats and
dogs were negative for neutralising antibodies. Previous studies using
European samples have shown a low level of infection, highest in Italy,
where 3.3% (15/451) of dog sera and 5.8% (11/191) cat sera collected
between March and May 2020 had measurable neutralising antibody
titres (Patterson et al., 2020a). These samples were purposefully
collected from regions of Italy with a high prevalence of infection in
humans, in some cases from households known to contain recently
diagnosed human cases. Our results in contrast, are more consistent with
a survey from a similar population of cats in Germany, that found 0/221
samples collected in April and May of 2020 to be positive for
anti-SARS-CoV-2 antibodies using ELISA (Michelitsch et al., 2020), and
with a survey in the Netherlands in April–May 2020, that found 0.4% of
cats and 0.2% of dogs to be seropositive (Zhao et al., 2021a). The lack of
positive samples from March–April 2020 in the UK, that we report here,
likely reflects the selection criteria of the animals assayed (undergoing
routine haematological testing and not selected based on location), and
the relatively low rate of human disease at the time compared to Italy.
In sera collected during the second wave of the pandemic, 4/287
(1.4%) dogs and 2/90 (2.2%) cats tested positive for SARS-CoV-2 neu-
tralising antibodies. Positive dog samples were collected in November
2020 and January and February of 2021. Positive cat samples were
collected in January 2021. This is again broadly in line with a recent
German survey conducted from September 2020 to February 2021,
showing a seroprevalence of 1.36% (increased from 0.69% earlier in the
pandemic), that the authors concluded corresponded with the rise of3
reported cases in the human population, and was suggestive of ongoing
transmission from owners to their cats (Michelitsch et al., 2021). The
detection of neutralising antibodies in dogs and cats during the second
wave in this study also likely reflects the increased numbers of humans
that had been infected. However, it is unknown whether the main variant
circulating in the UK human population during the second wave (B.1.1.7)
has altered transmissibility to cats and dogs as it does in humans (Davies
et al., 2021). Whilst there is some work in model species testing new
variants in e.g. hamsters (Nunez et al., 2021; Oa Donnell et al., 2021), to
our knowledge none of the early experimental infections performed in
cats and dogs using the original SARS-CoV-2 have been repeated with
newer variants.
Cats and dogs can be infected with other coronaviruses, leading to the
possibility that SARS-CoV-2 neutralising antibodies detected in this study
may result from previous infection with a different virus. We and others
have previously demonstrated a lack of cross-reactivity between SARS-
CoV-2 and samples containing antibodies to feline coronavirus (FCoV),
canine enteric coronavirus (CeCoV) and canine respiratory coronavirus
(CRCoV) (Michelitsch et al., 2020; Patterson et al., 2020a; Stevanovic
et al., 2021; Zhang et al., 2020). The reverse has also been demonstrated
whereby cat or dog samples containing antibodies to SARS-CoV-2 did not
react with known feline or canine coronavirus antigens (Michelitsch
et al., 2020; Zhao et al., 2021b). Here we also tested samples fromUK cats
and dogs collected before the human index case in the UK (21st January
2020 (Lillie et al., 2020)). All pre-COVID-19 samples were negative for
SARS-CoV-2 neutralising antibodies. Although there are no recent
sero-surveys of cat and dog coronaviruses in the UK (Addie and Jarrett,
1992; Priestnall et al., 2006; Stavisky et al., 2010), FCoV, CeCoV and
CRCoV are considered to be endemic. Furthermore, a recent serological
survey in the Netherlands testing for anti-SARS-CoV-2 antibodies also
found 71% of cat and 40% of dog pandemic sera to have antibodies to
other known cat or dog coronaviruses (Zhao et al., 2021a). If
cross-reactivity of SARS-CoV-2 with antibodies to cat and dog corona-
viruses was occurring in the study reported here, this would be apparent
in the pre-COVID-19 samples. We would also expect to see higher
numbers of animals with SARS-CoV-2 neutralising antibodies in the
pandemic samples, again suggesting that antibodies produced following
infection by endemic cat and dog coronaviruses do not cross-react with
SARS-CoV-2.
Here we made use of samples collected from a commercial diagnostic
laboratory contributing data to a voluntary national surveillance scheme
(SAVSNET) to efficiently test for evidence of prior SARS-CoV-2 infection
in UK cats and dogs. The major limitations of such a system are the
relatively sparse data available for each sample such that individual
animals, that are not identifiable, may have been sampled twice or have
come from the same household. In addition, such samples lack detailed
information on the health of the animals and whether they were from a
COVID-19-positive household. However, acquiring such samples from
the UK Virtual Biobank, offers a responsive resource for studying national
patterns of disease in UK pets (Smith et al., 2021).
We report here the detection of a low level of SARS-CoV-2 neutral-
ising antibodies in dogs and cats during the second wave of human in-
fections in the UK. The use of a neutralisation assay will not detect
animals that have sero-converted but not produced neutralising anti-
bodies (such that might test positive by ELISA but not by PRNT). Indeed,
other studies have shown that sera positive by ELISA for anti-SARS-CoV-2
antibodies may not have detectable neutralising antibodies (Michelitsch
et al., 2020; Zhao et al., 2021b). As such, our results may underestimate
the number of animals exposed to SARS-CoV-2.
We and others report that cats and dogs can become infected with
SARS-CoV-2, likely through their interactions with humans. Although
animal-to-animal transmission has been reported, for example on mink
farms and in experimental infections (Bosco-Lauth et al., 2020; Halfmann
et al., 2020; Shi et al., 2020; van Aart et al., 2021; Oreshkova et al.,
2020), the small numbers of companion animals testing positive in the
field in the UK and elsewhere suggest that pets are not currently acting as
S.L. Smith et al. Current Research in Virological Science 2 (2021) 100011a significant reservoir for infection, and that the pandemic will be
controlled by measures largely focussed on minimising human-to-human
transmission. Current UK guidance is that COVID-19 positive humans
should limit contact with their pets. Studies like that presented here
strongly argue for continued surveillance of in-contact, susceptible ani-
mal species, particularly with the emergence of new variants, which will
help determine whether in the future, more targeted control measures
are needed for pet animals, particularly in regions that are gaining con-
trol of infection in their human populations.
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